AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12750250 — intervention group
Group type: COMPARATOR
Intervention: Vegetable protein equivalent to high red meat diet
Number of subjects: 21
Study 12750250 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg supplement of haem iron
Number of subjects: 21
Study 12750250 — intervention group
Group type: EXPERIMENTAL
Intervention: 35-mg ferrous iron
Number of subjects: 21
Study 10893688 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prevalent vertebral fractures (VFX)
Number of subjects: 751
Study 10893688 — intervention group
Group type: COMPARATOR
Intervention: Patients without prevalent vertebral fractures (VFX)
Number of subjects: 751
Study 10893688 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of VFX
Number of subjects: 751
Study 10893688 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a single VFX
Number of subjects: 751
Study 10893688 — intervention group
Group type: EXPERIMENTAL
Intervention: NHP and EQ-5D scores
Number of subjects: 751
Study 8815701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with two nucleosides
Number of subjects: 0
Study 8815701 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 0
Study 1475040 — intervention group
Group type: EXPERIMENTAL
Intervention: 1750 mg of the DA antagonist alpha‐methyl‐p‐tyrosine (AMPT)
Number of subjects: 80
Study 1475040 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g/kg ethanol
Number of subjects: 80
Study 1475040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31517759 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace personal-fitness management program (PP) led by physical therapist, individualized for 6 months
Number of subjects: 60
Study 31517759 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received a 90-minute group-fitness management course
Number of subjects: 60
Study 30481808 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film breakup time (TBUT) measurement
Number of subjects: 0
Study 30481808 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis based on symptoms and TBUT test
Number of subjects: 0
Study 27400469 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoction of Nicotiana tabacum leaves mouthwash (10 mL 3 times a day for 5 days)
Number of subjects: 60
Study 27400469 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash (10 mL 3 times a day for 5 days)
Number of subjects: 60
Study 25210961 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcostal suture (TS)
Number of subjects: 30
Study 25210961 — intervention group
Group type: COMPARATOR
Intervention: Pericostal suture (PS)
Number of subjects: 30
Study 22302182 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (supplementary coffee intake)
Number of subjects: 30
Study 22302182 — intervention group
Group type: COMPARATOR
Intervention: Baseline MPI (caffeine-abstinent)
Number of subjects: 30
Study 20590751 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.5 pmol/kg/min)
Number of subjects: 6
Study 20590751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 17645577 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T3 (50 microg qd) for 3 weeks
Number of subjects: 20
Study 17645577 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 20
Study 16236864 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 18 months
Number of subjects: 95
Study 16236864 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who could not tolerate CPAP)
Number of subjects: 95
Study 12098564 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN) 1b therapy
Number of subjects: 10
Study 12098564 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study 10642067 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-HBO2 (breathing 95% O2 at 2.5 atm abs for 90 min)
Number of subjects: 12
Study 10642067 — intervention group
Group type: COMPARATOR
Intervention: Exercise-no HBO2
Number of subjects: 12
Study 10642067 — intervention group
Group type: COMPARATOR
Intervention: No exercise-HBO2
Number of subjects: 12
Study 10642067 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 8618852 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma HIV-1 RNA levels at delivery (190,400-1,664,100 copies/ml)
Number of subjects: 30
Study 8618852 — intervention group
Group type: COMPARATOR
Intervention: Maternal plasma HIV-1 RNA levels at delivery (500-155,800 copies/ml)
Number of subjects: 30
Study 8618852 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral RNA level < or = 100,000 copies/ml
Number of subjects: 30
Study 8618852 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial HIV-1 RNA levels during pregnancy
Number of subjects: 30
Study 2157829 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m (99mTc) imaging
Number of subjects: 316
Study 2157829 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-123 (123I) imaging
Number of subjects: 316
Study 2157829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytologic/histologic examination
Number of subjects: 316
Study 2157829 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of 123I scans
Number of subjects: 316
Study 2157829 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine reimaging of 99mTc hot nodules with radioiodine
Number of subjects: 316
Study 6104976 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 4
Study 6104976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimiterol
Number of subjects: 4
Study 6104976 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol and Rimiterol (equivalent molar amounts)
Number of subjects: 4
Study 26689935 — intervention group
Group type: COMPARATOR
Intervention: Anodal stimulation on left DLPFC
Number of subjects: 20
Study 26689935 — intervention group
Group type: COMPARATOR
Intervention: Cathodal stimulation on left DLPFC
Number of subjects: 20
Study 27977568 — intervention group
Group type: EXPERIMENTAL
Intervention: Human patient simulator intervention
Number of subjects: 191
Study 27977568 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 191
Study 27977568 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching session attendance rates
Number of subjects: 191
Study 25187119 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate 5 mg (N=703)
Number of subjects: 1054
Study 25187119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=351)
Number of subjects: 1054
Study 24145806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aintree technique via classic laryngeal mask airway (cLMA)
Number of subjects: 80
Study 24145806 — intervention group
Group type: COMPARATOR
Intervention: Fastrach technique via intubating laryngeal mask airway (iLMA)
Number of subjects: 80
Study 22045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous celecoxib 200 mg/day
Number of subjects: 858
Study 22045833 — intervention group
Group type: COMPARATOR
Intervention: Intermittent celecoxib 200 mg/day
Number of subjects: 858
Study 19553715 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal Filtek Supreme XT + Flowable Filtek XT
Number of subjects: 72
Study 19553715 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal Filtek Supreme XT + Dyract Flow
Number of subjects: 72
Study 19553715 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z250 + Flowable Filtek XT
Number of subjects: 72
Study 19553715 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z250 + Dyract Flow
Number of subjects: 72
Study 19553715 — intervention group
Group type: COMPARATOR
Intervention: Universal Filtek Supreme XT
Number of subjects: 72
Study 19553715 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z250
Number of subjects: 72
Study 19553715 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 72
Study 19553715 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable compomer
Number of subjects: 72
Study 19553715 — intervention group
Group type: EXPERIMENTAL
Intervention: LED light curing units (LCUs)
Number of subjects: 72
Study 19553715 — intervention group
Group type: EXPERIMENTAL
Intervention: QTH light curing units (LCUs)
Number of subjects: 72
Study 17216681 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with prevalent vertebral fracture
Number of subjects: 3798
Study 17216681 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with at least 3 prevalent vertebral fractures
Number of subjects: 3798
Study 15134769 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dominant view (embedded word)
Number of subjects: 0
Study 15134769 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects aware of the embedded word
Number of subjects: 0
Study 11474724 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining committing social blunders (Study 1)
Number of subjects: 0
Study 11474724 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing a public intellectual failure (Studies 2 and 3)
Number of subjects: 0
Study 11474724 — intervention group
Group type: EXPERIMENTAL
Intervention: Being described in an embarrassing way (Study 4)
Number of subjects: 0
Study 9562222 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI123 (201.0±37.9W)
Number of subjects: 10
Study 9562222 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI135 (176.1±27.6W)
Number of subjects: 10
Study 9562222 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI345 (164.0±22.8W)
Number of subjects: 10
Study 7881454 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivariate random effects model for pharmacokinetic variables (AUC and CMAX)
Number of subjects: 0
Study 7881454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size formula
Number of subjects: 0
Study 2905153 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 4.4 mg
Number of subjects: 24
Study 2905153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31788985 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin (8-24 mg/d)
Number of subjects: 302
Study 31788985 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (2-6 mg/d)
Number of subjects: 302
Study 31788985 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin
Number of subjects: 302
Study 31788985 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 302
Study 31788985 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin and Risperidone
Number of subjects: 302
Study 30660443 — intervention group
Group type: EXPERIMENTAL
Intervention: CTY‐5339A (14% benzocaine/2% tetracaine)
Number of subjects: 50
Study 30660443 — intervention group
Group type: COMPARATOR
Intervention: 14% benzocaine
Number of subjects: 50
Study 30660443 — intervention group
Group type: EXPERIMENTAL
Intervention: CTY‐5339A
Number of subjects: 50
Study 30660443 — intervention group
Group type: EXPERIMENTAL
Intervention: CTY‐5339A and 14% benzocaine
Number of subjects: 50
Study 28059603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery Learning (ML) BLS course
Number of subjects: 43
Study 28059603 — intervention group
Group type: COMPARATOR
Intervention: Time-Based (TB) BLS course
Number of subjects: 43
Study 25782427 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 supplementation (1000 μm phylloquinone, one pearl softgel capsule daily for 4 weeks)
Number of subjects: 82
Study 25782427 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one placebo capsule daily for 4 weeks)
Number of subjects: 82
Study 23681143 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative IV lidocaine (2 mg·kg·h)
Number of subjects: 116
Study 21870317 — intervention group
Group type: EXPERIMENTAL
Intervention: VibroX (vibration exercise with superimposed resistance exercise and vascular occlusion)
Number of subjects: 21
Study 19342294 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200mg total; 100mg capsule three hours before and remaining dose one hour before daytime recovery sleep)
Number of subjects: 0
Study 19342294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19342294 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 17660909 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-loaded ITI implants (loaded 6 weeks after surgery)
Number of subjects: 50
Study 17660909 — intervention group
Group type: COMPARATOR
Intervention: Conventionally-loaded ITI implants (loaded 12 weeks after surgery)
Number of subjects: 50
Study 15851312 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced QRS duration (measured in ms)
Number of subjects: 1026
Study 15851312 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced QRS duration
Number of subjects: 1026
Study 12227482 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral finasteride (1 mg per day)
Number of subjects: 100
Study 12227482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of finasteride and topical minoxidil
Number of subjects: 100
Study 12227482 — intervention group
Group type: COMPARATOR
Intervention: Topical 2% minoxidil solution
Number of subjects: 100
Study 12227482 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride with topical ketoconazole
Number of subjects: 100
Study 9849288 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0
Study 9849288 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study 8143406 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined tip design enteroclysis tube
Number of subjects: 0
Study 8143406 — intervention group
Group type: EXPERIMENTAL
Intervention: Corsafe tube
Number of subjects: 0
Study 8143406 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanically assisted infusion of methylcellulose
Number of subjects: 0
Study 8143406 — intervention group
Group type: COMPARATOR
Intervention: Other 10F enteroclysis tubes
Number of subjects: 0
Study 2644531 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential methotrexate and fluorouracil followed by leucovorin
Number of subjects: 679
Study 1058091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuva Seal
Number of subjects: 104
Study 1058091 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoxy‐Lite 9075
Number of subjects: 104
Study 1058091 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsealed teeth)
Number of subjects: 104
Study 29858517 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural injections
Number of subjects: 24
Study 29858517 — intervention group
Group type: COMPARATOR
Intervention: Intraneural injections
Number of subjects: 24
Study 23666832 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed home-based daily iron therapy (DOHBIT)
Number of subjects: 1059
Study 23666832 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised self-treatment at home
Number of subjects: 1059
Study 23216534 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for primary care physicians
Number of subjects: 67
Study 23216534 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (reference group)
Number of subjects: 67
Study 22010015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulanermin 8 mg/kg for 5 days with paclitaxel and carboplatin (arm 2)
Number of subjects: 213
Study 22010015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulanermin 8 mg/kg for 5 days with paclitaxel, carboplatin, and bevacizumab (arm 4)
Number of subjects: 213
Study 22010015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulanermin 20 mg/kg for 2 days with paclitaxel, carboplatin, and bevacizumab (arm 5)
Number of subjects: 213
Study 22010015 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin alone (arm 1)
Number of subjects: 213
Study 22010015 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel, carboplatin, and bevacizumab alone (arm 3)
Number of subjects: 213
Study 18288936 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg once daily)
Number of subjects: 433
Study 18288936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 433
Study 18288936 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 433
Study 16613190 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration therapy
Number of subjects: 0
Study 16613190 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐sizer
Number of subjects: 0
Study 16613190 — intervention group
Group type: EXPERIMENTAL
Intervention: AngioJet
Number of subjects: 0
Study 12844472 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-mineral drug combination containing dimethylaminoethanol (DMAE)
Number of subjects: 80
Study 12844472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9705050 — intervention group
Group type: COMPARATOR
Intervention: Thyroxine (T4) or tri‐iodothyronine (T3) or placebo
Number of subjects: 25
Study 7890006 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (Gab) infusion after liver resection
Number of subjects: 12
Study 7890006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study 2778501 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg daily oral sobrerol for 7 days
Number of subjects: 20
Study 2778501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 568917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow and Gate V formula
Number of subjects: 94
Study 568917 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Milk Plus
Number of subjects: 94
Study 568917 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium
Number of subjects: 94
Study 568917 — intervention group
Group type: COMPARATOR
Intervention: Breastfed
Number of subjects: 94
Study 31084488 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone (40 mg) and lidocaine (1.5 mL) injection into the glenohumeral joint 8 weeks after surgery (group 1)
Number of subjects: 80
Study 31084488 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (group 2)
Number of subjects: 80
Study 28218420 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and/or folic acid treatment
Number of subjects: 200
Study 28218420 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 200
Study 24949728 — intervention group
Group type: EXPERIMENTAL
Intervention: Advagraf
Number of subjects: 19
Study 24949728 — intervention group
Group type: COMPARATOR
Intervention: Prograf
Number of subjects: 19
Study 23078958 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg per day)
Number of subjects: 670
Study 23078958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study 23078958 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (with first-cycle rash)
Number of subjects: 670
Study 23078958 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (without first-cycle rash)
Number of subjects: 670
Study 23078958 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 670
Study 19005755 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, amoxicillin, metronidazole, and bismuth subcitrate (Group A)
Number of subjects: 120
Study 19005755 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole, amoxicillin, and clarithromycin (Group B)
Number of subjects: 120
Study 19005755 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole, amoxicillin‐clavulanic acid, and metronidazole (Group C)
Number of subjects: 120
Study 17568284 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive harvest (group A)
Number of subjects: 100
Study 17568284 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (group C)
Number of subjects: 100
Study 17568284 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive technique (group B)
Number of subjects: 100
Study 15193939 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronisation tapping
Number of subjects: 0
Study 15193939 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation tapping
Number of subjects: 0
Study 15193939 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiate phase
Number of subjects: 0
Study 15193939 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronise phase
Number of subjects: 0
Study 15193939 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue phase
Number of subjects: 0
Study 12199276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (15-30 mg/day)
Number of subjects: 0
Study 12199276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9815239 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable nucleoside reverse transcriptase inhibitor therapy
Number of subjects: 387
Study 9815239 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 387
Study 7656926 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid replacement therapy (TRT)
Number of subjects: 372
Study 7656926 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 372
Study 7656926 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 372
Study 2486951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg every 12 hrs for 5 days
Number of subjects: 60
Study 2486951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentiazac 100 mg every 12 hrs for 5 days
Number of subjects: 60
Study 2486951 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid 500 mg every 8 hrs for 5 days
Number of subjects: 60
Study 351570 — intervention group
Group type: EXPERIMENTAL
Intervention: Live instruction
Number of subjects: 60
Study 351570 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped instruction
Number of subjects: 60
Study 351570 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60
Study 31836203 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable soft contact lenses (Dailies Total 1, Dailies Aqua Comfort, TruEye, Biotrue Oneday)
Number of subjects: 32
Study 31836203 — intervention group
Group type: COMPARATOR
Intervention: No lens wear
Number of subjects: 32
Study 31191639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional modulation‐based SMR neurofeedback training (six-session protocol)
Number of subjects: 0